This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Development and validation of GMI signature based random survival forest prognosis model to predict clinical outcome in acute myeloid leukemia
BMC Medical Genomics Open Access 26 June 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.
Theilgaard-Mönch K, Boultwood J, Ferrari S, Giannopoulos K, Hernandez-Rivas JM, Kohlmann A et al. Gene expression profiling in MDS and AML: potential and future avenues. Leukemia 2011; 25: 909–920.
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354–365.
Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev 2009; 23: 877–889.
Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264–278.
Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506–510.
Miller CA, Wilson RK, Ley TJ . Genomic landscapes and clonality of de novo AML. N Engl J Med 2013; 369: 1473.
Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328–333.
Jan M, Majeti R . Clonal evolution of acute leukemia genomes. Oncogene 2012; 32: 135–140.
Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R . Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA 2014; 111: 2548–2553.
Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012; 4: 149ra118.
Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJM et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia 2013; 27: 852–860.
Schuster-Böckler B, Lehner B . Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature 2012; 488: 504–507.
Rapin N, Bagger FO, Jendholm J, Mora-Jensen H, Krogh A, Kohlmann A et al. Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. Blood 2014; 123: 894–904.
Marstrand TT, Borup R, Willer A, Borregaard N, Sandelin A, Porse BT, Theilgaard-Mönch K . A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia. Leukemia 2010; 24: 1265–1275.
Acknowledgements
This work was supported by grants from the Danish Council for Strategic Research (grant numbers 09-065157 BTP, 10-092798 BTP and 133100153 KT-M), the Danish Cancer Society (grant number R72-A4572-13-S2, KT-M), the Novo Nordisk Foundation (grant number 34220, KT-M), the Lundbeck Foundation (grant number 29367, KT-M) and through a center grant from the Novo Nordisk Foundation (The Novo Nordisk Foundation Section for Stem Cell Biology in Human Disease, BTP). This work is based on the joint research activities under the framework of the European Program for Cooperation in Science and Technology (COST, Action BM0801, WG1). LB was supported in part by the Deutsche Forschungsgemeinschaft (Heisenberg-Stipendium BU 1339/3-1) and KT-M is supported by a clinical research fellowship from the Novo Nordisk Foundation (grant number 100191).
Author Contributions
HM-J, JJ, NR, NB, BTP and KT-M conceived and designed the study; NB, LB, MKA and AR provided BM samples; HM-J, JJ, MKA and KT-M collected and assembled the data; HM-J, JJ, NR, FOB, OW, NB, BTP and KT-M analyzed and interpreted the data; KT-M drafted the manuscript. HM-J, JJ, NR, MKA, LB, NB and BTP contributed to the writing of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Mora-Jensen, H., Jendholm, J., Rapin, N. et al. Cellular origin of prognostic chromosomal aberrations in AML patients. Leukemia 29, 1785–1789 (2015). https://doi.org/10.1038/leu.2015.30
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.30
This article is cited by
-
Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy
Leukemia (2021)
-
Development and validation of GMI signature based random survival forest prognosis model to predict clinical outcome in acute myeloid leukemia
BMC Medical Genomics (2019)
-
The multifaceted functions of C/EBPα in normal and malignant haematopoiesis
Leukemia (2016)